2022 Compound Screening Disease 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . million in 2022 to 12.7 In the US alone, AD prevalence is expected to increase from 6.5
Drug Discovery World
JANUARY 26, 2023
The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at large and the pharmaceutical industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. However, that is not to say it was an easy year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 23, 2023
There was an urgent need for quick and adaptable drug discovery in the context of a complex and poorly understood disease. Our goal was to quickly identify existing therapeutics that could be repurposed for Covid-19 treatment by screening a library of approved and late-stage development drugs against a disease model in our platform.
Drug Discovery World
AUGUST 15, 2023
Cardiovascular diseases are the leading cause of death globally. A more recent analysis has illustrated how both assay validity and reproducibility correlate across a population of simulated screening and disease models 2. 3 argued that the choice of screening and disease models often depends on tradition or availability.
Broad Institute
JULY 26, 2022
Resources, services, and tools By Maria Nemchuk July 26, 2022 Breadcrumb Home Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators. Learn more PRISM Rapid, high-throughput multiplexed compound screening in genomically characterized human cancer cell-line models.
Expert insights. Personalized for you.
130 
Let's personalize your content